| Title |
Current status of bevacizumab in advanced ovarian cancer
|
|---|---|
| Published in |
OncoTargets and therapy, July 2013
|
| DOI | 10.2147/ott.s46301 |
| Pubmed ID | |
| Authors |
Federica Tomao, Anselmo Papa, Luigi Rossi, Davide Caruso, Pierluigi Benedetti Panici, Martina Venezia, Silverio Tomao |
| Abstract |
Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 9% |
| United States | 1 | 5% |
| Unknown | 19 | 86% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 41% |
| Student > Ph. D. Student | 4 | 18% |
| Other | 3 | 14% |
| Student > Bachelor | 1 | 5% |
| Student > Master | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 32% |
| Medicine and Dentistry | 6 | 27% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Business, Management and Accounting | 1 | 5% |
| Psychology | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2013.
All research outputs
#16,188,873
of 25,584,565 outputs
Outputs from OncoTargets and therapy
#879
of 2,967 outputs
Outputs of similar age
#120,531
of 207,028 outputs
Outputs of similar age from OncoTargets and therapy
#17
of 33 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,967 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,028 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.